Catalent (NYSE:CTLT) had its price objective increased by equities research analysts at Jefferies Financial Group from $44.00 to $50.00 in a research note issued on Tuesday, The Fly reports. The brokerage presently has a “hold” rating on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 16.96% from the company’s current price. Jefferies Financial Group also issued estimates for Catalent’s Q4 2019 earnings at $0.63 EPS, FY2019 earnings at $1.71 EPS, Q1 2020 earnings at $0.21 EPS, Q2 2020 earnings at $0.46 EPS, Q3 2020 earnings at $0.45 EPS, Q4 2020 earnings at $0.73 EPS and FY2020 earnings at $1.85 EPS.
CTLT has been the topic of several other research reports. Zacks Investment Research lowered Catalent from a “buy” rating to a “hold” rating in a research note on Thursday, February 7th. First Analysis reissued an “outperform” rating and set a $49.00 price target on shares of Catalent in a research note on Tuesday, March 5th. TheStreet raised Catalent from a “c” rating to a “b-” rating in a research note on Wednesday, February 6th. ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a research note on Wednesday, February 20th. Finally, UBS Group raised Catalent from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $43.00 to $54.00 in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Catalent currently has a consensus rating of “Buy” and a consensus target price of $49.57.
NYSE CTLT opened at $42.75 on Tuesday. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.63 and a current ratio of 2.08. Catalent has a 12-month low of $29.23 and a 12-month high of $46.43. The company has a market cap of $6.47 billion, a price-to-earnings ratio of 26.89, a price-to-earnings-growth ratio of 2.43 and a beta of 1.69.
Catalent (NYSE:CTLT) last released its earnings results on Tuesday, February 5th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.08. Catalent had a return on equity of 17.42% and a net margin of 5.48%. The company had revenue of $623.00 million for the quarter, compared to analysts’ expectations of $608.38 million. During the same quarter in the previous year, the firm posted $0.45 EPS. The firm’s quarterly revenue was up 2.8% on a year-over-year basis. As a group, equities research analysts forecast that Catalent will post 1.69 EPS for the current year.
In other news, insider Aristippos Gennadios sold 3,392 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $42.18, for a total transaction of $143,074.56. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP William Downie sold 7,315 shares of the business’s stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $42.00, for a total value of $307,230.00. The disclosure for this sale can be found here. Insiders have sold a total of 54,326 shares of company stock worth $2,303,676 in the last three months. Corporate insiders own 1.40% of the company’s stock.
A number of hedge funds have recently bought and sold shares of CTLT. JPMorgan Chase & Co. lifted its stake in Catalent by 29.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock valued at $363,316,000 after buying an additional 1,819,020 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its stake in Catalent by 3,074.3% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,798,868 shares of the company’s stock valued at $58,000 after buying an additional 1,742,199 shares in the last quarter. Norges Bank purchased a new stake in Catalent in the 4th quarter valued at approximately $47,177,000. Vanguard Group Inc lifted its stake in Catalent by 9.4% in the 3rd quarter. Vanguard Group Inc now owns 12,925,639 shares of the company’s stock valued at $588,763,000 after buying an additional 1,110,779 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Catalent by 9.4% in the 3rd quarter. Vanguard Group Inc. now owns 12,925,639 shares of the company’s stock valued at $588,763,000 after buying an additional 1,110,779 shares in the last quarter. 99.82% of the stock is currently owned by hedge funds and other institutional investors.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More: How Do Mutual Funds Work?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.